ARTICLE | Company News
ProteoTech, Tasly Pharmaceutical neurology news
October 11, 2010 7:00 AM UTC
The companies partnered to co-develop ProteoTech's Exebryl-1 to treat mild-to-moderate Alzheimer's disease (AD). Tasly will have rights in China, and ProteoTech retains rights elsewhere. ProteoTech s...